Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine

Pediatrics

Volumn 118, Issue 4, 2006, Pages 1422-1430

  LeBaron, Charles W ^a,c   Bi, Daoling ^a   Sullivan, Bradley J ^b   Beck, Carol ^b   Gargiullo, Paul ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b MARSHFIELD CLINIC   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adverse reactions; Dose schedule; Measles; Mumps; Rubella vaccine; Second dose

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ARTHRALGIA; ARTICLE; CHILD; CLINICAL EVALUATION; COMMON COLD; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE DURATION; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; INCIDENCE; INFORMATION PROCESSING; LYMPHADENOPATHY; MALE; MEDICAL SOCIETY; NAUSEA; NORMAL HUMAN; PHARYNGITIS; PRIORITY JOURNAL; RASH; RATING SCALE; SYMPTOMATOLOGY; VOMITING; AGE; COMPARATIVE STUDY; HEALTH MAINTENANCE ORGANIZATION; INFANT; PRESCHOOL CHILD; PROSPECTIVE STUDY; STATISTICS;

AGE FACTORS; CHILD; CHILD, PRESCHOOL; DIARRHEA; EXANTHEMA; FEMALE; FEVER; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; PROSPECTIVE STUDIES;

EID: 33750142055     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-0678     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. Measles prevention. Recommendations of the immunization practices advisory committee (ACIP). MMWR Morb Mortal Wkly Rep. 1989;38(suppl 9):1-18
2. American Academy of Pediatrics, Committee on Infectious Diseases. Measles: reassessment of the current immunization policy. Pediatrics. 1989;84:1110-1113
3. Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis. 2004;189(suppl 1):S43-S47
4. Centers for Disease Control and Prevention. Achievements in public health: elimination of rubella and congenital rubella syndrome - United States, 1969-2004. MMWR Morb Mortal Wkly Rep. 2005;54:279-282
5. Centers for Disease Control and Prevention. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 1998;47(RR-8):1-57
6. American Academy of Pediatrics, Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mump-rubella vaccine. Pediatrics. 1998;101:129-133
7. Tulchinsky TH, Ginsberg GM, Abed Y, Angeles MT, Akukwe C, Bonn J. Measles control in developing and developed countries: the case for a 2-dose policy. Bull WHO. 1993;71:93-103
8. de Quadros CA, Izurieta H, Venczel L, Carrasco P. Measles eradication in the Americas: progress to date. J Infect Dis. 2004;189(suppl 1):S227-S235
9. Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet. 1998;351:356-361
10. Jansen VAA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science. 2003;301:804
11. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles,-mumps-rubella vaccine. Lancet. 1986;i:939-942
12. Chen RT, Moses JM, Markowitz LE, Orenstein WA. Adverse events following measles-mumps-rubella vaccinations in college students. Vaccine. 1991;9:297-299
13. Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years of age: a comparison of adverse clinical events after immunization in the vaccine safety datalink project. Pediatrics. 1997;100:767-771
14. Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics. 2000;106(5). Available at: www.pediatrics.org/cgi/content/ full/106/5/e62
15. Gothfors L, Bergstrom E, Backman M. Immunogenicity and reactogenicity of a new measles, mumps, and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis. 2001;33:545-549
16. Kaye JA, Meloro-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. Br Med J. 2001;322:460-463
17. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA. 2004;292:351-357
18. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997;99:765-773
19. US Census Bureau. County and City Data Book: 2000, 13th ed. Washington, DC: US Census Bureau; 2001:64-65
20. Kohl KS, Bonhoeffer J, Chen R, et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf. 2003;12:1-6
21. Marcy SM, Kohl KS, Dagan R, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine. 2004;22:551-556